Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort

H. Nina Kim, Carla V. Rodriguez, Stephen Van Rompaey, Joseph J. Eron, Chloe L Thio, Heidi M. Crane, Edgar T. Overton, Michael S. Saag, Jeffrey Martin, Elvin Geng, Michael Mugavero, Benigno Rodriguez, W. Christopher Mathews, Stephen Boswell, Richard D Moore, Mari M. Kitahata

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV. We examined the effect of prior lamivudine (3TC) treatment and other factors on HBV DNA suppression with TDF in a multisite clinical cohort of coinfected patients. METHODS: We studied all patients enrolled in the Centers for AIDS Research Network of Integrated Clinical Systems cohort from 1996 to 2011 who had chronic HBV and HIV infection, initiated a TDF-based regimen continued for ≥3 months and had on-treatment HBV DNA measurements. We used Kaplan-Meier curves and Cox-proportional hazards to estimate time to suppression (HBV DNA level 10,000 IU/mL, and lower nadir CD4 count were independently associated with decreased likelihood of HBV DNA suppression on TDF. CONCLUSIONS: These results emphasize the role of prior 3TC exposure and immune response on delayed HBV suppression on TDF.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume66
Issue number1
DOIs
StatePublished - May 1 2014

Fingerprint

Tenofovir
Hepatitis B virus
Hepatitis
HIV
Lamivudine
DNA
Virus Diseases
Chronic Hepatitis B
CD4 Lymphocyte Count

Keywords

  • hepatitis B virus
  • HIV
  • lamivudine
  • tenofovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. / Kim, H. Nina; Rodriguez, Carla V.; Van Rompaey, Stephen; Eron, Joseph J.; Thio, Chloe L; Crane, Heidi M.; Overton, Edgar T.; Saag, Michael S.; Martin, Jeffrey; Geng, Elvin; Mugavero, Michael; Rodriguez, Benigno; Mathews, W. Christopher; Boswell, Stephen; Moore, Richard D; Kitahata, Mari M.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 66, No. 1, 01.05.2014, p. 96-101.

Research output: Contribution to journalArticle

Kim, HN, Rodriguez, CV, Van Rompaey, S, Eron, JJ, Thio, CL, Crane, HM, Overton, ET, Saag, MS, Martin, J, Geng, E, Mugavero, M, Rodriguez, B, Mathews, WC, Boswell, S, Moore, RD & Kitahata, MM 2014, 'Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort', Journal of Acquired Immune Deficiency Syndromes, vol. 66, no. 1, pp. 96-101. https://doi.org/10.1097/QAI.0000000000000126
Kim, H. Nina ; Rodriguez, Carla V. ; Van Rompaey, Stephen ; Eron, Joseph J. ; Thio, Chloe L ; Crane, Heidi M. ; Overton, Edgar T. ; Saag, Michael S. ; Martin, Jeffrey ; Geng, Elvin ; Mugavero, Michael ; Rodriguez, Benigno ; Mathews, W. Christopher ; Boswell, Stephen ; Moore, Richard D ; Kitahata, Mari M. / Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. In: Journal of Acquired Immune Deficiency Syndromes. 2014 ; Vol. 66, No. 1. pp. 96-101.
@article{897c5b03627040f7a3529211d2392385,
title = "Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort",
abstract = "BACKGROUND: Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV. We examined the effect of prior lamivudine (3TC) treatment and other factors on HBV DNA suppression with TDF in a multisite clinical cohort of coinfected patients. METHODS: We studied all patients enrolled in the Centers for AIDS Research Network of Integrated Clinical Systems cohort from 1996 to 2011 who had chronic HBV and HIV infection, initiated a TDF-based regimen continued for ≥3 months and had on-treatment HBV DNA measurements. We used Kaplan-Meier curves and Cox-proportional hazards to estimate time to suppression (HBV DNA level 10,000 IU/mL, and lower nadir CD4 count were independently associated with decreased likelihood of HBV DNA suppression on TDF. CONCLUSIONS: These results emphasize the role of prior 3TC exposure and immune response on delayed HBV suppression on TDF.",
keywords = "hepatitis B virus, HIV, lamivudine, tenofovir",
author = "Kim, {H. Nina} and Rodriguez, {Carla V.} and {Van Rompaey}, Stephen and Eron, {Joseph J.} and Thio, {Chloe L} and Crane, {Heidi M.} and Overton, {Edgar T.} and Saag, {Michael S.} and Jeffrey Martin and Elvin Geng and Michael Mugavero and Benigno Rodriguez and Mathews, {W. Christopher} and Stephen Boswell and Moore, {Richard D} and Kitahata, {Mari M.}",
year = "2014",
month = "5",
day = "1",
doi = "10.1097/QAI.0000000000000126",
language = "English (US)",
volume = "66",
pages = "96--101",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort

AU - Kim, H. Nina

AU - Rodriguez, Carla V.

AU - Van Rompaey, Stephen

AU - Eron, Joseph J.

AU - Thio, Chloe L

AU - Crane, Heidi M.

AU - Overton, Edgar T.

AU - Saag, Michael S.

AU - Martin, Jeffrey

AU - Geng, Elvin

AU - Mugavero, Michael

AU - Rodriguez, Benigno

AU - Mathews, W. Christopher

AU - Boswell, Stephen

AU - Moore, Richard D

AU - Kitahata, Mari M.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - BACKGROUND: Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV. We examined the effect of prior lamivudine (3TC) treatment and other factors on HBV DNA suppression with TDF in a multisite clinical cohort of coinfected patients. METHODS: We studied all patients enrolled in the Centers for AIDS Research Network of Integrated Clinical Systems cohort from 1996 to 2011 who had chronic HBV and HIV infection, initiated a TDF-based regimen continued for ≥3 months and had on-treatment HBV DNA measurements. We used Kaplan-Meier curves and Cox-proportional hazards to estimate time to suppression (HBV DNA level 10,000 IU/mL, and lower nadir CD4 count were independently associated with decreased likelihood of HBV DNA suppression on TDF. CONCLUSIONS: These results emphasize the role of prior 3TC exposure and immune response on delayed HBV suppression on TDF.

AB - BACKGROUND: Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV. We examined the effect of prior lamivudine (3TC) treatment and other factors on HBV DNA suppression with TDF in a multisite clinical cohort of coinfected patients. METHODS: We studied all patients enrolled in the Centers for AIDS Research Network of Integrated Clinical Systems cohort from 1996 to 2011 who had chronic HBV and HIV infection, initiated a TDF-based regimen continued for ≥3 months and had on-treatment HBV DNA measurements. We used Kaplan-Meier curves and Cox-proportional hazards to estimate time to suppression (HBV DNA level 10,000 IU/mL, and lower nadir CD4 count were independently associated with decreased likelihood of HBV DNA suppression on TDF. CONCLUSIONS: These results emphasize the role of prior 3TC exposure and immune response on delayed HBV suppression on TDF.

KW - hepatitis B virus

KW - HIV

KW - lamivudine

KW - tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84898548348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898548348&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000126

DO - 10.1097/QAI.0000000000000126

M3 - Article

C2 - 24500175

AN - SCOPUS:84898548348

VL - 66

SP - 96

EP - 101

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -